OMI · Owens & Minor Inc/Va/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.76B | $10.70B | $10.33B | $9.96B | $9.79B | $8.48B |
| Cost of Revenue | $1.47B | $8.48B | $8.21B | $8.13B | $8.27B | $7.20B |
| Gross Profit | $1.29B | $2.22B | $2.13B | $1.83B | $1.51B | $1.28B |
| R&D | - | $13.00M | $12.10M | - | - | - |
| SG&A | $1.07B | $1.91B | $1.81B | $1.63B | $1.12B | $1.04B |
| Total Operating Expenses | $2.90B | - | - | - | - | - |
| D&A | $214.52M | $264.77M | $287.38M | $228.67M | $90.62M | $93.34M |
| Operating Income | $27.46M | ($207.77M) | $104.51M | $142.91M | $368.47M | $204.12M |
| Interest Expense | $107.18M | $143.80M | $157.91M | $128.89M | $48.09M | $83.40M |
| Income Tax | $729.0K | $5.33M | ($13.43M) | ($11.50M) | $55.16M | $21.83M |
| Net Income | ($1.10B) | ($362.69M) | ($41.30M) | $22.39M | $221.59M | $29.87M |
| EPS - Basic | ($14.31) | ($4.73) | ($0.54) | $0.30 | $0.47 | - |
| EPS - Diluted | ($14.31) | ($4.73) | ($0.54) | $0.29 | $0.47 | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $281.99M | $49.38M | $243.04M | $69.47M | $55.71M | $83.06M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | $74.44M | $1.13B | $1.11B | $1.33B | $1.50B | $1.23B |
| Accounts Payable | $363.56M | $1.25B | $1.17B | $1.15B | $1.00B | $1.00B |
| Current Assets | $547.87M | $2.02B | $2.10B | $2.30B | $2.32B | $2.14B |
| Total Assets | $2.45B | $4.66B | $5.09B | $5.39B | $3.54B | $3.34B |
| Current Liabilities | $947.08M | $1.87B | $1.89B | $1.57B | $1.34B | $1.35B |
| Long-term Debt | - | - | - | - | - | $1.51B |
| Total Liabilities | $2.91B | $4.09B | $4.17B | $4.44B | $2.60B | $2.62B |
| Stockholders' Equity | ($460.98M) | $565.23M | $924.17M | $945.60M | $938.50M | $712.05M |
| Retained Earnings | ($1.08B) | $6.02M | $368.71M | $410.01M | $387.62M | $167.02M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $161.50M | $161.50M | $740.71M | $325.01M | $124.18M | $339.22M |
| Investing Cash Flow | $144.42M | ($116.53M) | ($137.25M) | ($1.80B) | ($53.63M) | $80.07M |
| Financing Cash Flow | $188.08M | ($267.60M) | ($417.33M) | $1.50B | ($129.48M) | ($379.39M) |
| CapEx | $190.96M | $210.87M | $190.87M | $158.09M | $40.98M | $50.42M |
| Free Cash Flow | ($29.46M) | ($49.37M) | $549.84M | $166.92M | $83.19M | $288.80M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 46.7% | 20.7% | 20.6% | 18.3% | 15.5% | 15.1% |
| Operating margin | 1.0% | -1.9% | 1.0% | 1.4% | 3.8% | 2.4% |
| EBITDA margin | 8.8% | 0.5% | 3.8% | 3.7% | 4.7% | 3.5% |
| Net margin | -39.8% | -3.4% | -0.4% | 0.2% | 2.3% | 0.4% |
| Free cash flow margin | -1.1% | -0.5% | 5.3% | 1.7% | 0.9% | 3.4% |
| FCF / Net income | 0.03 | 0.14 | -13.31 | 7.46 | 0.38 | 9.67 |
| R&D / Revenue | - | 0.1% | 0.1% | - | - | - |
| SG&A / Revenue | 38.7% | 17.8% | 17.5% | 16.4% | 11.4% | 12.3% |
| Effective tax rate | - | - | - | -105.6% | 19.9% | 42.2% |
| Return on assets | -44.9% | -7.8% | -0.8% | 0.4% | 6.3% | 0.9% |
| Return on equity | 238.8% | -64.2% | -4.5% | 2.4% | 23.6% | 4.2% |
| Return on invested capital | - | - | - | - | - | 5.3% |
| Liquidity | ||||||
| Current ratio | 0.58 | 1.08 | 1.11 | 1.47 | 1.73 | 1.59 |
| Quick ratio | 0.50 | 0.47 | 0.52 | 0.61 | 0.61 | 0.67 |
| Cash ratio | 0.30 | 0.03 | 0.13 | 0.04 | 0.04 | 0.06 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | 2.12 |
| Debt / Assets | - | - | - | - | - | 0.45 |
| Debt / EBITDA | - | - | - | - | - | 5.07 |
| Interest coverage | 0.3x | -1.4x | 0.7x | 1.1x | 7.7x | 2.4x |
| Equity multiplier | -5.32 | 8.24 | 5.51 | 5.70 | 3.77 | 4.68 |
| Liabilities / Assets | 1.19 | 0.88 | 0.82 | 0.82 | 0.73 | 0.79 |
| Efficiency | ||||||
| Asset turnover | 1.13 | 2.30 | 2.03 | 1.85 | 2.77 | 2.54 |
| Inventory turnover | 19.79 | 7.49 | 7.39 | 6.10 | 5.53 | 5.84 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 18d | 49d | 49d | 60d | 66d | 63d |
| Days payable outstanding | 90d | 54d | 52d | 52d | 44d | 51d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -74.2% | 3.6% | 3.8% | 1.7% | 15.4% | -7.9% |
| Revenue CAGR (3y) | -34.8% | 3.0% | 6.8% | 2.6% | 0.2% | -4.5% |
| Revenue CAGR (5y) | -20.1% | 3.0% | 1.2% | 0.5% | - | - |
| Gross profit growth (YoY) | -41.9% | 4.4% | 16.4% | 20.7% | 18.1% | 13.5% |
| Operating income growth (YoY) | - | - | -26.9% | -61.2% | 80.5% | 179.0% |
| Net income growth (YoY) | -203.5% | -778.2% | - | -89.9% | 641.8% | - |
| EPS growth (YoY) | -202.5% | -775.9% | - | -38.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | -23.2% | - |
| FCF growth (YoY) | 40.3% | - | 229.4% | 100.6% | -71.2% | 133.5% |
| FCF CAGR (5y) | - | - | 50.7% | 49.8% | -13.0% | 19.2% |
| Book value growth (YoY) | - | -38.8% | -2.3% | 0.8% | 31.8% | 37.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$2.76B totalDiabetes Product$783.37M · 28.4%
Sleep Therapy Product$740.05M · 26.8%
Home Respiratory Therapy Product$433.05M · 15.7%
Product And Service Other$288.19M · 10.4%
Ostomy$212.84M · 7.7%
Wound Care$188.51M · 6.8%
Urology$116.02M · 4.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.60
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Wholesale-Medical, Dental & Hospital Equipment & Supplies
Comparing OWENS & MINOR INC/VA/ against the 2 most active filers in the same SIC group.